These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 21334734

  • 21. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 23. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.
    BMC Infect Dis; 2013 Feb 07; 13():75. PubMed ID: 23390964
    [Abstract] [Full Text] [Related]

  • 24. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.
    Eur J Cancer; 2015 Sep 07; 51(13):1732-41. PubMed ID: 26121913
    [Abstract] [Full Text] [Related]

  • 25. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.
    J Med Econ; 2010 Mar 07; 13(1):110-8. PubMed ID: 20085477
    [Abstract] [Full Text] [Related]

  • 26. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 27. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories, Public Health Services.
    J Infect; 2017 Apr 20; 74(4):393-400. PubMed ID: 28126492
    [Abstract] [Full Text] [Related]

  • 28. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA, Perry CM.
    Drugs; 2006 Apr 20; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [Abstract] [Full Text] [Related]

  • 29. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A, Ovcinnikova O, Palmer C, Engelbrecht K, Reuschenbach M, Daniels V.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2437703. PubMed ID: 39365579
    [Abstract] [Full Text] [Related]

  • 30. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
    Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, Radley D, Vuocolo S, Haupt RM, Saah A.
    PLoS One; 2013 Oct 01; 8(12):e83431. PubMed ID: 24391768
    [Abstract] [Full Text] [Related]

  • 31. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 01; 13(1):100-10. PubMed ID: 22075170
    [Abstract] [Full Text] [Related]

  • 32. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, Lee IH.
    Asian Pac J Cancer Prev; 2018 Apr 25; 19(4):933-940. PubMed ID: 29693347
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 Apr 25; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 34. Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection.
    Chapman R, Soldan K, Jit M.
    Vaccine; 2011 Apr 05; 29(16):2881-6. PubMed ID: 21338682
    [Abstract] [Full Text] [Related]

  • 35. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, Wang W, Palmer C.
    J Med Econ; 2023 Apr 05; 26(1):1085-1098. PubMed ID: 37608730
    [Abstract] [Full Text] [Related]

  • 36. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 37. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC, Gray P, Bender N, Eriksson T, Kann H, Apter D, Paavonen J, Pajunen E, Prager KM, Sehr P, Surcel HM, Waterboer T, Müller M, Pawlita M, Lehtinen M.
    Lancet Infect Dis; 2021 Oct 20; 21(10):1458-1468. PubMed ID: 34081923
    [Abstract] [Full Text] [Related]

  • 38. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
    Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.
    Acta Obstet Gynecol Scand; 2009 Oct 20; 88(1):27-35. PubMed ID: 19031282
    [Abstract] [Full Text] [Related]

  • 39. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 40. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.
    Bresse X, Adam M, Largeron N, Roze S, Marty R.
    Hum Vaccin Immunother; 2013 Apr 01; 9(4):823-33. PubMed ID: 23563511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.